Lifetech LAmbre™ Left Atrial Appendage Closure System Post-Market Registry

Last updated: November 26, 2022
Sponsor: Lifetech Scientific (Shenzhen) Co., Ltd.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Atrial Fibrillation

Chest Pain

Dysrhythmia

Treatment

N/A

Clinical Study ID

NCT04307927
LA-PMCF-02
  • Ages > 18
  • All Genders

Study Summary

Single-center, single-arm, prospective, post-market study of LAmbre™ LAA Closure System. To evaluate immediate and long term procedural success of Lifetech LAmbre™ occluders in patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

    1. Patients must be at least 18 years of age; 2. Patients with non-valvularparoxysmal, persistent or permanent atrial fibrillation with long-term sustainabilityscheduled for interventional LAA closure; 3. Patient characteristics consistent withthe corresponding IFU and sizing guidelines*; 4. The patient or legally authorizedrepresentative has been informed of the nature of the study, agrees to its provisionsand has provided written informed consent, approved by the appropriate EthicsCommittee (EC); 5. The patient agrees to comply with requirements of the studyincluding the 24 months follow- up.

Exclusion

Exclusion Criteria:

    1. Any contra-indication mentioned in the corresponding IFU*; 2. Currentlyparticipating in other investigational drug- or device studies; 3. Patient who ispregnant, planning to become pregnant, or breast feeding; 4. Patients cannot toleratetransoesophageal echocardiogram (TEE).
  • Note: In IFU, the Left Atrial Appendage Closure System is contraindicated for thefollowing: • Patients' LAA anatomy not suitable for the REF of the device.
  • Patients' with intracardiac thrombus.
  • Patients with active endocarditis or other infections causing bacteremia.
  • Patients where placement of the device would interfere with any intracardiacor intravascular structures.
  • Patients with contraindications to X-Ray and/or trans-esophagealechocardiographic examinations.
  • Patients with known hypersensitivity to nickel.

Study Design

Total Participants: 100
Study Start date:
March 14, 2020
Estimated Completion Date:
December 31, 2025

Study Description

Detailed Description:

Atrial fibrillation (AF) is the most common cardiac arrhythmia causing ischemic stroke. The CHA2DS2-VASc score was developed to estimate the stroke rate in patients with non-valvular AF, and high scores predict a raised annual stroke risk. The yearly stroke risks without treatment in patients with CHA2DS2-VASc score 2 and 9 are 2.2% and 15.2% respectively. For patients with increased stroke risk (CHA2DS2-VASc score ≧2), warfarin or other novel oral anticoagulants (NOAC) recommended for stroke prevention. Despite the effectiveness of current pharmacological therapies for stroke prevention in atrial fibrillation, around 20% of patients discontinue therapy - whether new oral anticoagulants (NOAC) or warfarin because of side effects and/or bleeding. In addition, warfarin needs to be dosed individually to target an international normalized ratio (INR) of 2-3 for striking an optimal balance between bleeding and ischemic stroke events. This, combined with drug-drug interaction that occurs with both NOACs and warfarin, results in inadequate stroke protection in a substantial portion of AF patients. The LAA is the source of 90% of cardiac emboli attributed to stroke events. This is a windsock-like structure on the lateral border of the left atrium with internal trabeculations, and being a confined space, is prone to blood stasis and thrombus formation. Currently, there are surgical, epicardial and percutaneous techniques for occluding this structure in order to reduce stroke in AF patients cannot take long term oral anticoagulants, and the percutaneous route is intuitively the most attractive given its relative non-invasiveness. The two devices in most widespread use for percutaneous LAA closure worldwide are the Watchman (Boston Scientific, Natick, MA, USA) and the Amplatzer Cardiac Plug (ACP) (Abbott, IL, CA USA). However, both devices have limitations including the need for relatively large delivery sheaths (9-14 French) and limited recapture and repositioning capabilities.

LAmbreTM LAA Closure System (Lifetech Scientific, Shenzhen, China) is a novel self-expanding LAA occluder constructed from a nitinol mesh and polyester membranes and consists of an umbrella and a cover connected by a short central waist. The device is delivered by an 8-10 French sheath and has full recapture and repositioning capabilities. LAmbreTM LAA Closure System received the CE mark in June 2016.

This PMCF study will be carried out following the CE mark of LAmbreTM LAA Closure System and is intended to confirm the effectiveness and safety of LAmbreTM LAA Closure System.

Connect with a study center

  • Katholisches Klinikum Koblenz ·Montabaur

    Koblenz, 56073
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.